GlassScriptPhysician profile
Amanda C Dawson
NPI 1508329871
$2,097.55
in general payments reported to CMS, 2019-2025
25 companies · $786 in 2025
The $786 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.58 · 2022: $219 · 2023: $148 · 2024: $918 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,851.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $275.04 | 2022-2025 | |
| Corcept Therapeutics | $260.62 | 2024-2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $182.11 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $164.59 | 2024-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $135.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $106.27 | 2021-2025 | Dificid, Capvaxive, Gardasil 9 |
| Janssen Biotech, INC. | $105.44 | 2024-2025 | Tremfya, Stelara, Simponi |
| Novo Nordisk INC | $93.81 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $90.02 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.51 | 2024-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $79.00 | 2024-2025 | Resmetirom, Rezdiffra |
| Gilead Sciences, INC. | $71.83 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $58.39 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $51.93 | 2024-2025 | Entyvio |
| Pfizer INC. | $49.69 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.96 | 2022-2023 | Eliquis |
| Lilly USA, LLC | $45.30 | 2025 | Jardiance, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $42.70 | 2025 | Austedo Xr |
| Daiichi Sankyo INC. | $28.28 | 2025 | Injectafer |
| Kyowa Kirin, INC. | $23.12 | 2025 | |
| Mylan Specialty L.P. | $22.66 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $21.33 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.19 | 2024 | Acthar |
| Sanofi Pasteur INC. | $21.17 | 2023 | |
| Dexcom, INC. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.